The former tends to have a more favorable track record in clinical outcomes and manageable side effects, contrasted by the challenges faced by anti-CD19 therapies in achieving predefined efficacy endpoints, raising important considerations for clinical practice and the selection of therapeutic strategies for patients with autoimmune disorders. The gene discussed is CD19; the disease is autoimmune disease.